Table 4.

Regression Analysis—Mortality Risk Among Children and Adolescents Initiating Antiretroviral Therapy in Central Kenya (2004–2014)

Outcome: mortality	Univariable results		Multivariable results
Imputed models	sHR (95% CI)	p	sHR (95% CI)	p
Age groups, years
0–4	Ref.		Ref.
5–9	1.08 (0.63–1.87)	.007	0.89 (0.47–1.66)	.703
10–14	1.61 (1.10–2.37)	.015	1.31 (0.83–2.06)	.252
15–19	0.65 (0.41–1.03)	<.001	0.56 (0.38–0.81)	.002
Sex
Female	Ref.		Ref.
Male	1.48 (1.02–2.15)	<.001	1.44 (0.93–2.23)	.099
Regimen
D4T Based	Ref.		Ref.
AZT Based	0.72 (0.40–1.31)	.916	0.86 (0.45–1.65)	.655
TDF based	0.26 (0.07–0.97)	.004	0.50 (0.13–1.93)	.313
ABC based	0.51 (0.26–0.98)	.221	0.69 (0.31–1.54)	.363
Baseline WHO stage
Stage I	Ref.		Ref.
Stage II	2.13 (0.99–4.57)	.902	1.87 (0.91–3.83)	.090
Stage III	3.44 (1.51–7.82)	.599	2.44 (1.15–5.16)	.020
Stage IV	5.49 (2.18–13.86)	.237	3.62 (1.20–10.89)	.022
TB status
No signs	Ref.		Ref.
On TB treatment	13.85 (6.60–29.04)	.593	11.89 (5.51–25.65)	<.001
Presumptive TB	6.71 (3.37–13.37)	.001	5.76 (2.82–11.76)	<.001

AZT, zidovudine; D4T, stavudine; sHR, subhazard ratios; TX, treatment; WHO, World Health Organization.